Janssen Biologics, a European subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), says it has withdrawn its application to change the marketing authorization for Simponi (golimumab) to add a new form of intravenous (IV) administration for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).
Janssen Biologics informed the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) of its decision following receipt of an assessment report that indicated additional clinical data were required to further evaluate the risk:benefit profile of the IV formulation.
"We have elected to withdraw our application seeking approval of Simponi IV in the European Union as we are unable at this time to provide additional clinical data beyond the pivotal Phase III results included in the current submission," said Newman Yeilding, head of immunology development at Janssen Research & Development, adding: "While we are disappointed that we will be unable to pursue the approval of Simponi IV as a treatment for moderately to severely active rheumatoid arthritis in the European Union, we are confident that the Phase III data accumulated through the Simponi IV clinical development program demonstrate a positive risk:benefit profile for this anti-tumor necrosis factor (TNF)-alpha therapy."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze